OS

OneStream, Inc. Class A Common Stock
Inactive Not actively trading
$24.00
+0.00 (+0.00%)
Mkt Cap 2.40B
Volume 2,661,330
52W Range 16.51-29.66
Sector Technology
Beta 1.99
EPS (TTM) -0.28 USD
P/E Ratio -65.64
Revenue (TTM) 601.93M USD
Rev Growth (5Y) +29.2%
EPS Growth (5Y) N/A
AlphaQuality · Ungradable
AlphaQuality requires 5 years of audited income statements; only 4 available.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022
Revenue 601.93M 489.41M 374.92M 279.32M
Net Income (50.30M) (216.20M) (28.93M) (65.47M)
EPS -0.28 -1.25 -0.85 -0.28
Free Cash Flow 95.63M 58.53M 18.68M (37.92M)
FCF / Share 0.53 0.34 0.12 -0.16
Operating CF 96.67M 61.15M 21.27M (32.94M)
Total Assets 1.03B 823.22M 361.56M 320.01M
Total Debt 14.80M 18.59M 20.03M 18.91M
Cash & Equiv 693.58M 544.17M 117.09M 14.69M
Book Value 504.71M 386.17M 106.53M 127.14M
Return on Equity -0.10 -0.56 -0.27 -0.51
OS News
OneStream (NASDAQ:OS) and Dassault Systemes (OTCMKTS:DASTY) Head to Head Analysis
Sep 23, 2026 10:15 PM · defenseworld.net
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Sep 14, 2026 08:00 PM · gurufocus.com
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
Sep 13, 2026 06:00 PM · gurufocus.com
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Sep 13, 2026 06:00 PM · gurufocus.com
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Sep 13, 2026 04:00 PM · gurufocus.com
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
Sep 13, 2026 04:00 AM · gurufocus.com
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Aug 25, 2026 04:00 AM · gurufocus.com
AstraZeneca Reports Positive Lung Cancer Trials Amid Pipeline Setback
Aug 17, 2026 07:14 AM · gurufocus.com
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal
Aug 05, 2026 05:00 PM · gurufocus.com
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
Jul 27, 2026 04:00 AM · gurufocus.com